The July meeting delivered a mix of outcomes, but almost every approval came with conditions. From osteoporosis and Crohn’s disease to multiple cancers and rare disorders, PBAC required steep price reductions and risk-sharing arrangements for PBS listing. …
PBAC delivers recommendations dominated by price cuts and risk shares
August 25, 2025 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Botanix appoints Dr Patricia Walker as a non-executive director
August 25, 2025 - - Australian Biotech -
First site initiated for Neuren’s Phelan-McDermid syndrome Phase 3 trial
August 25, 2025 - - Australian Biotech -
Argent BioPharma announces results of independent in vivo study
August 25, 2025 - - Australian Biotech -
An outcome that might haunt the system's decision-making, like Banquo's ghost
August 25, 2025 - - Latest News -
PBAC delivers recommendations dominated by price cuts and risk shares
August 25, 2025 - - Latest News -
Disappointment as committee stalls again on broad listing for cancer immunotherapies
August 25, 2025 - - Latest News -
World-first clinical trial reveals unprecedented insights into brain cancer treatment
August 24, 2025 - - Australian Biotech